Douglas Goodin, MD
Professor
Neurology
School of Medicine

Education & Training

Show all (1) Hide

• Residency School of Medicine - Neurology University of California, San Francisco

Websites

Show all (1) Hide

• Clinical Profile at UCSF Medical Center (ucsfhealth.org)

Publications (191)

Top publication keywords:
Interferon-betaMultiple SclerosisInterferon beta-1aReaction TimeEvoked Potentials, AuditoryDisability EvaluationAdjuvants, ImmunologicGenetic Predisposition to DiseaseEvoked PotentialsHaplotypesImmunologic FactorsMultiple Sclerosis, Relapsing-RemittingEvidence-Based MedicineRandomized Controlled Trials as TopicInterferon beta-1b

• Multiple sclerosis: Exploring the limits and implications of genetic and environmental susceptibility.
  PloS one 2023 Goodin DS, Khankhanian P, Gourraud PA, Vince N
• Remote Observational Research for Multiple Sclerosis: A Natural Experiment.
  Neurology(R) neuroimmunology & neuroinflammation 2022 Bove R, Poole S, Cuneo R, Gupta S, Sabatino J, Harms M, Cooper T, Rowles W, Miller N, Gomez R, Lincoln R, McPolin K, Powers K, Santaniello A, Renschen A, Bevan CJ, Gelfand JM, Goodin DS, Guo CY, Romeo…
• Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS".
  Annals of neurology 2022 Bischof A, Papinutto N, Keshavan A, Rajesh A, Kirkish G, Zhang X, Mallott JM, Asteggiano C, Sacco S, Gundel TJ, Zhao C, Stern WA, Caverzasi E, Zhou Y, Gomez R, Ragan NR, Santaniello A, Zhu AH, Juwono …
• Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis.
  Annals of neurology 2022 Bischof A, Papinutto N, Keshavan A, Rajesh A, Kirkish G, Zhang X, Mallott JM, Asteggiano C, Sacco S, Gundel TJ, Zhao C, Stern WA, Caverzasi E, Zhou Y, Gomez R, Ragan NR, Santaniello A, Zhu AH, Juwono …
• Genetic susceptibility to multiple sclerosis in African Americans.
  PloS one 2021 Goodin DS, Oksenberg JR, Douillard V, Gourraud PA, Vince N

Show all (186 more) Hide

• Genetic susceptibility to multiple sclerosis: interactions between conserved extended haplotypes of the MHC and other susceptibility regions.
  BMC medical genomics 2021 Goodin DS, Khankhanian P, Gourraud PA, Vince N
• The nature of genetic and environmental susceptibility to multiple sclerosis.
  PloS one 2021 Goodin DS, Khankhanian P, Gourraud PA, Vince N
• An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis.
  Multiple sclerosis (Houndmills, Basingstoke, England) 2020 Romeo AR, Rowles WM, Schleimer ES, Barba P, Hsu WY, Gomez R, Santaniello A, Zhao C, Pearce JR, Jones JB, Cree BC, Hauser SL, Gelfand JM, Stewart WF, Goodin DS, Bove RM
• Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS.
  AJNR. American journal of neuroradiology 2020 Sacco S, Caverzasi E, Papinutto N, Cordano C, Bischof A, Gundel T, Cheng S, Asteggiano C, Kirkish G, Mallott J, Stern WA, Bastianello S, Bove RM, Gelfand JM, Goodin DS, Green AJ, Waubant E, Wilson MR,…
• Silent progression in disease activity-free relapsing multiple sclerosis.
  Annals of neurology 2019 University of California, San Francisco MS-EPIC Team, Cree BAC, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E, Bischof A, Gundel T, Zhu AH, Papinutto N, Stern WA, Bevan C, Romeo A, Goodin DS,…
• Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
  Multiple sclerosis (Houndmills, Basingstoke, England) 2018 Goodin DS, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM, IFNB Multiple Sclerosis Study Group and the 16- and 21-…
• Reply to Tsivgoulis and colleagues comments.
  Multiple sclerosis and related disorders 2018 Goodin DS, Mitsikostas DD
• Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility.
  PloS one 2018 Goodin DS, Khankhanian P, Gourraud PA, Vince N
• Harnessing electronic medical records to advance research on multiple sclerosis.
  Multiple sclerosis (Houndmills, Basingstoke, England) 2018 Damotte V, Lizée A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, Gomez R, Lincoln R, Tang W, Chen T, Lee N, Villoslada P, Hollenbach JA, Bevan CD, Graves J, Bove R, Goodin DS, Green AJ, …
• Comparing the efficacy of disease-modifying therapies in multiple sclerosis.
  Multiple sclerosis and related disorders 2017 Mitsikostas DD, Goodin DS
• Long-term evolution of multiple sclerosis disability in the treatment era.
  Annals of neurology 2016 University of California, San Francisco MS-EPIC Team:, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von …
• Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.
  Journal of neurology 2016 Schippling S, O'Connor P, Knappertz V, Pohl C, Bogumil T, Suarez G, Cook S, Filippi M, Hartung HP, Comi G, Jeffery DR, Kappos L, Goodin DS, Arnason B
• The nature of genetic susceptibility to multiple sclerosis: constraining the possibilities.
  BMC neurology 2016 Goodin DS
• The epidemiology of multiple sclerosis: insights to a causal cascade.
  Handbook of clinical neurology 2016 Goodin DS
• Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
  JAMA neurology 2015 Fitzgerald KC, Munger KL, Köchert K, Arnason BG, Comi G, Cook S, Goodin DS, Filippi M, Hartung HP, Jeffery DR, O'Connor P, Suarez G, Sandbrink R, Kappos L, Pohl C, Ascherio A
• A comparative analysis of Patient-Reported Expanded Disability Status Scale tools.
  Multiple sclerosis (Houndmills, Basingstoke, England) 2015 Collins CD, Ivry B, Bowen JD, Cheng EM, Dobson R, Goodin DS, Lechner-Scott J, Kappos L, Galea I
• Relapses in multiple sclerosis: Relationship to disability.
  Multiple sclerosis and related disorders 2015 Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D, Racke MK, Trapp BD, Vartanian T, Waubant E
• Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.
  Journal of neurology 2015 Hartung HP, Kappos L, Goodin DS, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, White R, Bogumil T, Beckmann K, Stemper B, Suarez G, Sandbrink R, Pohl C
• Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis.
  JAMA neurology 2015 Schlaeger R, Papinutto N, Zhu AH, Lobach IV, Bevan CJ, Bucci M, Castellano A, Gelfand JM, Graves JS, Green AJ, Jordan KM, Keshavan A, Panara V, Stern WA, von Büdingen HC, Waubant E, Goodin DS, Cree BA…
• Haplotype-based approach to known MS-associated regions increases the amount of explained risk.
  Journal of medical genetics 2015 Khankhanian P, Gourraud PA, Lizee A, Goodin DS
• Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis.
  International journal of MS care 2015 Wilson LS, Loucks A, Gipson G, Zhong L, Bui C, Miller E, Owen M, Pelletier D, Goodin D, Waubant E, McCulloch CE
• Precision medicine in chronic disease management: The multiple sclerosis BioScreen.
  Annals of neurology 2014 Gourraud PA, Henry RG, Cree BA, Crane JC, Lizee A, Olson MP, Santaniello AV, Datta E, Zhu AH, Bevan CJ, Gelfand JM, Graves JS, Goodin DS, Green AJ, von Büdingen HC, Waubant E, Zamvil SS, Crabtree-…
• Causes of death among commercially insured multiple sclerosis patients in the United States.
  PloS one 2014 Goodin DS, Corwin M, Kaufman D, Golub H, Reshef S, Rametta MJ, Knappertz V, Cutter G, Pleimes D
• Spinal cord gray matter atrophy correlates with multiple sclerosis disability.
  Annals of neurology 2014 Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach IV, Bucci M, Caverzasi E, Gelfand JM, Green AJ, Jordan KM, Stern WA, von Büdingen HC, Waubant E, Zhu AH, Goodin DS, Cree BA, Hauser SL, Henry RG
• Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
  Journal of the neurological sciences 2014 Wilson L, Loucks A, Bui C, Gipson G, Zhong L, Schwartzburg A, Crabtree E, Goodin D, Waubant E, McCulloch C
• Single nucleotide polymorphism (SNP)-strings: an alternative method for assessing genetic associations.
  PloS one 2014 Goodin DS, Khankhanian P
• Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
  The Lancet. Neurology 2014 Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD
• Glucocorticoid treatment of multiple sclerosis.
  Handbook of clinical neurology 2014 Goodin DS
• Preface.
  Handbook of clinical neurology 2014 Goodin DS
• The epidemiology of multiple sclerosis: insights to disease pathogenesis.
  Handbook of clinical neurology 2014 Goodin DS
• Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S.
  Multiple sclerosis and related disorders 2013 Kaufman DW, Reshef S, Golub HL, Peucker M, Corwin MJ, Goodin DS, Knappertz V, Pleimes D, Cutter G
• Interleukin 17F level and interferon β response in patients with multiple sclerosis.
  JAMA neurology 2013 Hartung HP, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, Knappertz V, Bogumil T, Schwenke S, Croze E, Sandbrink R, Pohl C
• Mortality in patients with multiple sclerosis.
  Neurology 2013 Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC
• The use of interferon Beta and glatiramer acetate in multiple sclerosis.
  Seminars in neurology 2013 Goodin DS
• The genetic and environmental bases of complex human-disease: extending the utility of twin-studies.
  PloS one 2012 Goodin DS
• Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
  BMJ open 2012 Goodin DS, Ebers GC, Cutter G, Cook SD, O'Donnell T, Reder AT, Kremenchutzky M, Oger J, Rametta M, Beckmann K, Knappertz V
• Response to GS Gronseth and E Ashman.
  Multiple sclerosis (Houndmills, Basingstoke, England) 2012 Goodin DS, Reder AT
• Treatment with interferon beta for multiple sclerosis.
  JAMA 2012 Goodin DS, Reder AT, Cutter G
• Evidence-based medicine: promise and pitfalls.
  Multiple sclerosis (Houndmills, Basingstoke, England) 2012 Goodin DS, Reder AT
• Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies.
  Journal of neuroinflammation 2012 Hartung HP, Kieseier B, Goodin DS, Arnason BG, Comi G, Cook S, Filippi M, Jeffery DR, Kappos L, Bogumil T, Stemper B, Sandbrink R, Nakada Y, Nakajima H, Schwenke S, Lehr S, Heubach J, Pohl C, Reischl …
• Acute hypercalcemia following excessive calcium supplementation in a dehydrated patient with progressive multiple sclerosis: vitamin d supplementation is a red herring-reply.
  Archives of neurology 2012 Marcus JF, Goodin DS, Harris CA, Josephson SA
• Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes.
  PloS one 2012 Gelfand JM, Goodin DS, Boscardin WJ, Nolan R, Cuneo A, Green AJ
• Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.
  Neurology 2012 Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V
• Evidence-based guideline update: intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Clinical Neurophysiology Society.
  Neurology 2012 Nuwer MR, Emerson RG, Galloway G, Legatt AD, Lopez J, Minahan R, Yamada T, Goodin DS, Armon C, Chaudhry V, Gronseth GS, Harden CL, Therapeutics and Technology Assessment Subcommittee of the American …
• Evidence-based guideline update: intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials*.
  Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society 2012 Nuwer MR, Emerson RG, Galloway G, Legatt AD, Lopez J, Minahan R, Yamada T, Goodin DS, Armon C, Chaudhry V, Gronseth GS, Harden CL, American Association of Neuromuscular and Electrodiagnostic Medicine
• Severe hypercalcemia following vitamin d supplementation in a patient with multiple sclerosis: a note of caution.
  Archives of neurology 2012 Marcus JF, Shalev SM, Harris CA, Goodin DS, Josephson SA
• Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
  Journal of neurology, neurosurgery, and psychiatry 2011 Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC, 16-Year Long Term Follow-up Study Investigators
• Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
  Annals of neurology 2011 Patsopoulos NA, Bayer Pharma MS Genetics Working Group, Steering Committees of Studies Evaluating IFNß-1b and a CCR1-Antagonist, ANZgene Consortium, GeneMSA, International Multiple Sclerosis Genetics …
• Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.
  PloS one 2011 Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, Konieczny A, Knappertz V, 16-Year Long-Term Follow-up Study Investigators
• Incorporating neutralizing antibody assays into routine clinical practice: a long and arduous road.
  Multiple sclerosis (Houndmills, Basingstoke, England) 2011 Goodin DS
• Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
  Multiple sclerosis (Houndmills, Basingstoke, England) 2011 Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C, BEYOND Study Group
• Multiple Sclerosis: The Big Questions- The MS Forum Workshop.
  International MS journal 2011 Goodin D
• Interferon β-1b and glatiramer acetate effects on permanent black hole evolution.
  Neurology 2011 Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, Kappos L, Goodin D, Jeffery D, Hartung HP, Comi G, Wolinsky JS, Bogumil T, Pohl C, Beckmann K, Sandbrink R, Croze E, Brown C, Desimone…
• Switching multiple sclerosis patients with breakthrough disease to second-line therapy.
  PloS one 2011 Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E
• Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome.
  Neurology 2011 Okuda DT, Mowry EM, Cree BA, Crabtree EC, Goodin DS, Waubant E, Pelletier D
• The genetic basis of multiple sclerosis: a model for MS susceptibility.
  BMC neurology 2010 Goodin DS
• Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis.
  Annals of neurology 2010 Cree BA, Kornyeyeva E, Goodin DS
• Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
  Journal of neurology, neurosurgery, and psychiatry 2010 Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A, Investigators of the 16-year Long-Term Follow-Up Study
• Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
  Neurology 2010 Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A, Investigators of the 16-Year Long-Term Follow-Up Study
• Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.
  Multiple sclerosis (Houndmills, Basingstoke, England) 2009 Goodin DS, Bates D
• 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
  The Lancet. Neurology 2009 O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T, BEYOND Study Group, O…
• Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
  Clinical therapeutics 2009 Ebers GC, Reder AT, Traboulsee A, Li D, Langdon D, Goodin DS, Wolf C, Beckmann K, Konieczny A, Investigators of the 16-Year Long-Term Follow-Up Study
• Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures.
  Neurology 2009 Mowry EM, Beheshtian A, Waubant E, Goodin DS, Cree BA, Qualley P, Lincoln R, George MF, Gomez R, Hauser SL, Okuda DT, Pelletier D
• Results of using a wireless inertial measuring system to quantify gait motions in control subjects.
  IEEE transactions on information technology in biomedicine : a publication of the IEEE Engineering in Medicine and Biology Society 2009 Tien I, Glaser SD, Bajcsy R, Goodin DS, Aminoff MJ
• The 2nd world congress on controversies in neurology.
  International MS journal 2009 Goodin D
• Magnetic resonance imaging as a surrogate for treatment effect on multiple sclerosis relapses.
  Annals of neurology 2009 Arnold DL, Goodin DS
• The causal cascade to multiple sclerosis: a model for MS pathogenesis.
  PloS one 2009 Goodin DS
• Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome.
  Neurology 2008 Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, Hauser SL, Pelletier D
• Disease-modifying therapy in multiple sclerosis: update and clinical implications.
  Neurology 2008 Goodin DS
• Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures.
  Brain : a journal of neurology 2008 Okuda DT, Srinivasan R, Oksenberg JR, Goodin DS, Baranzini SE, Beheshtian A, Waubant E, Zamvil SS, Leppert D, Qualley P, Lincoln R, Gomez R, Caillier S, George M, Wang J, Nelson SJ, Cree BA, Hauser SL…
• Electrical brain events associated with awareness of errors.
  Brain research 2008 Ralph JW, Goodin DS, Long JM, Aminoff MJ
• Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis.
  Human molecular genetics 2008 Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, Geurts JJ, Kragt J, …
• Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
  Neurology 2008 Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
• The impact of war-stress on MS exacerbations.
  Annals of neurology 2008 Goodin DS
• Comparative studies of glatiramer acetate and interferon beta.
  International MS journal 2008 Goodin D
• Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
  Clinical therapeutics 2008 Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T
• Electrophysiological evaluation of dementia.
  Handbook of clinical neurology 2008 Aminoff MJ, Goodin DS
• Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis.
  Current medical research and opinion 2007 Goodin DS, Biermann LD, Bohlega S, Boiko A, Chofflon M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Karussis D, Miller A, Pakdaman H, Selmaj K, Sharief M, International Working Group for …
• Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
  Neurology 2007 Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, Stevens JC
• Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.
  The Journal of international medical research 2007 Goodin DS, Hurwitz B, Noronha A
• Age at disability milestones in multiple sclerosis and history of multiple sclerosis: a unifying concept.
  Brain : a journal of neurology 2006 Goodin D
• A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
  Neurology 2006 Goodin DS
• The use of MRI in the diagnosis of multiple sclerosis.
  The Lancet. Neurology 2006 Goodin D
• IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
  Neurology 2006 Goodin DS
• Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre.
  Journal of neurology 2006 Goodin DS
• The return of natalizumab: weighing benefit against risk.
  The Lancet. Neurology 2006 Goodin D
• Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?
  Annals of neurology 2006 Goodin DS
• Overdiagnosis of multiple sclerosis by magnetic resonance imaging.
  Annals of neurology 2006 Goodin DS, Frohman EM
• Evidence-based medicine.
  International MS journal 2005 Goodin DS
• Response to interferon beta-1a treatment in African American multiple sclerosis patients.
  Archives of neurology 2005 Cree BA, Al-Sabbagh A, Bennett R, Goodin D
• Treatment of multiple sclerosis with human beta interferon.
  International MS journal 2005 Goodin DS
• Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
  Journal of the neurological sciences 2005 Panitch H, Goodin D, Francis G, Chang P, Coyle P, O'Connor P, Li D, Weinshenker B, EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study
• Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
  Archives of neurology 2005 Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G, EVIDENCE (Evidence of Interferon Dose-Response: European North American …
• Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis.
  Neurology 2004 Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA, Glidden D, Weinstock-Guttman B, Reich D, Patterson N, Haines JL, Pericak-Vance M, DeLoa C, Oksenberg JR, Hauser SL
• Disease-modifying therapy in MS: a critical review of the literature. Part I: Analysis of clinical trial errors.
  Journal of neurology 2004 Goodin DS
• Disease-modifying therapy in MS: a critical review of the literature. Part II: Assessing efficacy and dose-response.
  Journal of neurology 2004 Goodin DS
• Assessment: transcranial Doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
  Neurology 2004 Sloan MA, Alexandrov AV, Tegeler CH, Spencer MP, Caplan LR, Feldmann E, Wechsler LR, Newell DW, Gomez CR, Babikian VL, Lefkowitz D, Goldman RS, Armon C, Hsu CY, Goodin DS, Therapeutics and Technology …
• Relationship between multiple sclerosis exacerbations and stress.
  Psychosomatic medicine 2004 Goodin DS
• Marijuana and multiple sclerosis.
  The Lancet. Neurology 2004 Goodin D
• Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans.
  American journal of human genetics 2003 Oksenberg JR, Barcellos LF, Cree BA, Baranzini SE, Bugawan TL, Khan O, Lincoln RR, Swerdlin A, Mignot E, Lin L, Goodin D, Erlich HA, Schmidt S, Thomson G, Reich DE, Pericak-Vance MA, Haines JL, Hauser…
• Stimulus recognition and its relationship to the cerebral event-related potential.
  Neurology 2003 Leppert D, Goodin DS, Aminoff MJ
• The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
  Neurology 2003 Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
• The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
  Neurology 2003 Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH, Therapeutics and …
• Interferons in relapsing remitting multiple sclerosis.
  Lancet (London, England) 2003 Goodin DS
• HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course.
  American journal of human genetics 2003 Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E, Goodin DS, Pelletier D, Lincoln RR, Bucher P, Swerdlin A, Pericak-Vance MA, Haines JL, Hauser SL, Multiple Sclerosis …
• Disease-modifying Therapies for Multiple Sclerosis.
  Current treatment options in neurology 2003 Corboy JR, Goodin DS, Frohman EM
• Neuromyelitis optica.
  Seminars in neurology 2002 Cree BA, Goodin DS, Hauser SL
• Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
  Neurology 2002 Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology …
• Assessment: prevention of post-lumbar puncture headaches: report of the therapeutics and technology assessment subcommittee of the american academy of neurology.
  Neurology 2000 Evans RW, Armon C, Frohman EM, Goodin DS
• Clinical utility of surface EMG: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology.
  Neurology 2000 Pullman SL, Goodin DS, Marquinez AI, Tabbal S, Rubin M
• Therapeutic developments in multiple sclerosis.
  Expert opinion on investigational drugs 2000 Goodin DS
• Studies of the human stretch reflex.
  Muscle & nerve. Supplement 2000 Aminoff MJ, Goodin DS
• The cladribine trial in secondary progressive MS: response.
  Neuroepidemiology 2000 Goodin DS
• Changes of forearm EMG and cerebral evoked potentials following sudden muscle stretch in patients with Huntington's disease.
  Muscle & nerve 1999 Siedenberg R, Goodin DS, Aminoff MJ
• The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
  Neurology 1999 Goodin DS, Ebers GC, Johnson KP, Rodriguez M, Sibley WA, Wolinsky JS
• Order effects in response times of parkinsonian patients and normal controls.
  Muscle & nerve 1999 Goodin DS, Aminoff MJ, Kutukcu Y, Marks WJ
• Survey of multiple sclerosis in northern California. Northern California MS Study Group.
  Multiple sclerosis (Houndmills, Basingstoke, England) 1999 Goodin DS
• Interferon beta treatment for multiple sclerosis.
  Lancet (London, England) 1999 Goodin DS
• Simple and choice reaction time in Parkinson's disease.
  Brain research 1999 Kutukcu Y, Marks WJ, Goodin DS, Aminoff MJ
• Cognitive event-related potentials. The International Federation of Clinical Neurophysiology.
  Electroencephalography and clinical neurophysiology. Supplement 1999 Heinze HJ, Münte TF, Kutas M, Butler SR, Näätänen R, Nuwer MR, Goodin DS
• Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis.
  Neuroepidemiology 1999 Goodin DS
• Somatosensory evoked potentials. The International Federation of Clinical Neurophysiology.
  Electroencephalography and clinical neurophysiology. Supplement 1999 Mauguière F, Allison T, Babiloni C, Buchner H, Eisen AA, Goodin DS, Jones SJ, Kakigi R, Matsuoka S, Nuwer M, Rossini PM, Shibasaki H
• A questionnaire to assess neurological impairment in multiple sclerosis.
  Multiple sclerosis (Houndmills, Basingstoke, England) 1998 Goodin DS
• Cerebral accompaniments to simple and choice reaction tasks in Parkinson's disease.
  Brain research 1998 Kutukcu Y, Marks WJ, Goodin DS, Aminoff MJ
• Cognitive event-related potentials.
  Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society 1998 Goodin DS
• Event-related potentials in the study of sensory discrimination and motor response in simple and choice reaction tasks.
  Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society 1998 Goodin DS, Aminoff MJ
• The decision to make a movement: neurophysiological insights.
  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1997 Aminoff MJ, Goodin DS
• Changes of forearm EMG and cerebral evoked potentials following sudden muscle stretch during isometric contractions in patients with Parkinson's disease.
  Brain research 1997 Aminoff MJ, Siedenberg R, Goodin DS
• Response compatibility and the relationship between event-related potentials and the timing of a motor response.
  Journal of neurophysiology 1996 Goodin DS, Aminoff MJ, Chequer RS, Ortiz TA
• Nonrandom behavior in a reaction-time time series.
  Muscle & nerve 1996 Goodin DS, Aminoff MJ
• Comparison of late components in simultaneously recorded event-related electrical potentials and event-related magnetic fields.
  Electroencephalography and clinical neurophysiology 1996 Siedenberg R, Goodin DS, Aminoff MJ, Rowley HA, Roberts TP
• Response times and handedness in simple reaction-time tasks.
  Experimental brain research 1996 Goodin DS, Aminoff MJ, Ortiz TA, Chequer RS
• Side effect profile of interferon beta-1b in MS: results of an open label trial.
  Neurology 1996 Neilley LK, Goodin DS, Goodkin DE, Hauser SL
• The frontal N30 component of the median-derived SEP in patients with predominantly unilateral Parkinson's disease.
  Neurology 1995 Garcia PA, Aminoff MJ, Goodin DS
• Visual evoked potentials.
  Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society 1994 Aminoff MJ, Goodin DS
• Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging.
  Annals of neurology 1994 Husted CA, Goodin DS, Hugg JW, Maudsley AA, Tsuruda JS, de Bie SH, Fein G, Matson GB, Weiner MW
• In vivo detection of myelin phospholipids in multiple sclerosis with phosphorus magnetic resonance spectroscopic imaging.
  Annals of neurology 1994 Husted CA, Matson GB, Adams DA, Goodin DS, Weiner MW
• IFCN recommended standards for brain-stem auditory evoked potentials. Report of an IFCN committee. International Federation of Clinical Neurophysiology.
  Electroencephalography and clinical neurophysiology 1994 Nuwer MR, Aminoff M, Goodin D, Matsuoka S, Mauguière F, Starr A, Vibert JF
• IFCN recommended standards for long-latency auditory event-related potentials. Report of an IFCN committee. International Federation of Clinical Neurophysiology.
  Electroencephalography and clinical neurophysiology 1994 Goodin D, Desmedt J, Maurer K, Nuwer MR
• IFCN recommended standards for short latency somatosensory evoked potentials. Report of an IFCN committee. International Federation of Clinical Neurophysiology.
  Electroencephalography and clinical neurophysiology 1994 Nuwer MR, Aminoff M, Desmedt J, Eisen AA, Goodin D, Matsuoka S, Mauguière F, Shibasaki H, Sutherling W, Vibert JF
• Late electromyographic activity following stretch in human forearm muscles: physiological role.
  Brain research 1994 Chequer RS, Goodin DS, Aminoff MJ, Maeztu C
• Treatment of optic neuritis.
  Neurology 1993 Goodin DS
• Expectancy and response strategy to sensory stimuli.
  Neurology 1993 Goodin DS, Aminoff MJ, Ortiz TA
• Neural processing in a three-choice reaction-time task: a study using cerebral evoked-potentials and single-trial analysis in normal humans.
  Journal of neurophysiology 1993 Ortiz TA, Goodin DS, Aminoff MJ
• Corticosteroids and optic neuritis.
  Neurology 1993 Goodin DS
• Evaluation of dementia by event-related potentials.
  Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society 1992 Goodin DS, Aminoff MJ
• The basis and functional role of the late EMG activity in human forearm muscles following wrist displacement.
  Brain research 1992 Goodin DS, Aminoff MJ
• Effect of different high-pass filters on the long-latency event-related auditory evoked potentials in normal human subjects and individuals infected with the human immunodeficiency virus.
  Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society 1992 Goodin DS, Aminoff MJ, Chequer RS
• The nature of suprasegmental influences on the late reflex activity in human forearm muscles.
  Brain research 1991 Chequer RS, Goodin DS, Aminoff MJ
• The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review.
  Neurology 1991 Goodin DS
• A comparison of magnetic and electrical stimulation of peripheral nerves.
  Muscle & nerve 1990 Olney RK, So YT, Goodin DS, Aminoff MJ
• Organization of sensory discrimination and response selection in choice and nonchoice conditions: a study using cerebral evoked potentials in normal humans.
  Journal of neurophysiology 1990 Goodin DS, Aminoff MJ, Shefrin SL
• Evidence that the long-latency stretch responses of the human wrist extensor muscle involve a transcerebral pathway.
  Brain : a journal of neurology 1990 Goodin DS, Aminoff MJ, Shih PY
• Clinical utility of long latency 'cognitive' event-related potentials (P3): the pros.
  Electroencephalography and clinical neurophysiology 1990 Goodin DS
• Long latency event-related potentials in patients infected with human immunodeficiency virus.
  Annals of neurology 1990 Goodin DS, Aminoff MJ, Chernoff DN, Hollander H
• Detection of epileptiform activity by different noninvasive EEG methods in complex partial epilepsy.
  Annals of neurology 1990 Goodin DS, Aminoff MJ, Laxer KD
• Electrophysiological features of the dementia of Parkinson's disease.
  Advances in neurology 1990 Aminoff MJ, Goodin A, Goodin DS
• Effects of different sensory inputs on the median-derived somatosensory evoked potential.
  Muscle & nerve 1989 Reisin RC, Goodin DS, Aminoff MJ, Mantle MM
• Effect of reference point on visual evoked potentials: clinical relevance.
  Electroencephalography and clinical neurophysiology 1988 Shih PY, Aminoff MJ, Goodin DS, Mantle MM
• Recovery of peripheral and central responses to median nerve stimulation.
  Electroencephalography and clinical neurophysiology 1988 Reisin RC, Goodin DS, Aminoff MJ, Mantle MM
• Dermatomal somatosensory evoked potentials in lumbosacral root compression.
  Journal of neurology, neurosurgery, and psychiatry 1988 Aminoff MJ, Goodin DS
• Ambulatory EEG recordings in epileptic and nonepileptic children.
  Neurology 1988 Aminoff MJ, Goodin DS, Berg BO, Compton MN
• Magnetic resonance imaging in amyotrophic lateral sclerosis.
  Annals of neurology 1988 Goodin DS, Rowley HA, Olney RK
• PD and ciladopa.
  Neurology 1988 Goodin DS, Aminoff MJ
• Visual evoked potentials in the investigation of "blindsight".
  Neurology 1988 Shefrin SL, Goodin DS, Aminoff MJ
• Sensory discrimination and its relationship to the cerebral processing of infrequent stimuli.
  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1987 Goodin DS, Aminoff MJ, Mantle MM
• Treatment of Parkinson's disease with ciladopa.
  Annals of neurology 1987 Aminoff MJ, Goodin DS, Habermann-Little B, Cutler JR
• Electrophysiological differences between demented and nondemented patients with Parkinson's disease.
  Annals of neurology 1987 Goodin DS, Aminoff MJ
• Electrophysiological evidence of visual processing in a blind field.
  Electroencephalography and clinical neurophysiology. Supplement 1987 Shefrin SL, Goodin DS, Aminoff MJ
• The distinction between different types of dementia using evoked potentials.
  Electroencephalography and clinical neurophysiology. Supplement 1987 Goodin DS, Aminoff MJ
• Electrophysiological differences between subtypes of dementia.
  Brain : a journal of neurology 1986 Goodin DS, Aminoff MJ
• Subclasses of event-related potentials: response-locked and stimulus-locked components.
  Annals of neurology 1986 Goodin DS, Aminoff MJ, Mantle MM
• P300 latency as a biologic marker of dementia.
  Biological psychiatry 1986 Goodin DS
• Acute syphilitic meningitis. Its occurrence after clinical and serologic cure of secondary syphilis with penicillin G.
  Archives of neurology 1986 Bayne LL, Schmidley JW, Goodin DS
• Electrophysiologic evaluation of lumbosacral radiculopathies: electromyography, late responses, and somatosensory evoked potentials.
  Neurology 1985 Aminoff MJ, Goodin DS, Parry GJ, Barbaro NM, Weinstein PR, Rosenblum ML
• Electrophysiologic evaluation of dementia.
  Neurologic clinics 1985 Goodin DS
• Task-dependent hemisphere asymmetries of the visual evoked potential.
  Neurology 1985 Goodin DS, Waltz DA, Aminoff MJ
• Dermatomal somatosensory evoked potentials in unilateral lumbosacral radiculopathy.
  Annals of neurology 1985 Aminoff MJ, Goodin DS, Barbaro NM, Weinstein PR, Rosenblum ML
• Does the interictal EEG have a role in the diagnosis of epilepsy?
  Lancet (London, England) 1984 Goodin DS, Aminoff MJ
• The relationship between the evoked potential and brain events in sensory discrimination and motor response.
  Brain : a journal of neurology 1984 Goodin DS, Aminoff MJ
• Sequential changes in the P3 component of the auditory evoked potential in confusional states and dementing illnesses.
  Neurology 1983 Goodin DS, Starr A, Chippendale T, Squires KC
• Variations in early and late event-related components of the auditory evoked potential with task difficulty.
  Electroencephalography and clinical neurophysiology 1983 Goodin DS, Squires KC, Starr A
• Long latency event-related components of the auditory evoked potential in dementia.
  Brain : a journal of neurology 1978 Goodin DS, Squires KC, Starr A
• An early event-related cortical potential.
  Psychophysiology 1978 Goodin DS, Squires KC, Henderson BH, Starr A
• Age-related variations in evoked potentials to auditory stimuli in normal human subjects.
  Electroencephalography and clinical neurophysiology 1978 Goodin DS, Squires KC, Henderson BH, Starr A
• Mutant of bacteriophage T4D affecting expression of many early genes.
  Nature 1974 Mattson T, Richardson J, Goodin D